Streetbeat News

Analyst Ratings

SFM

Sprouts Farmers Market (NASDAQ:SFM) reported Q3 earnings of $0.65 per share, beating the analyst consensus estimate of $0.62 by 4.84%. The company also reported quarterly sales of $1.71 billion, surpassing the analyst consensus estimate of $1.68 billion by 1.96%. Both earnings and sales show an increase compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:23 pm

XLO

Xilio Therapeutics, Inc. (NASDAQ:XLO) will host a virtual investor conference call and webcast on November 6, 2023, to review progress across its pipeline of tumor-activated molecules, including Phase 1/2 clinical data for XTX202. The data will be presented at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:22 pm

CYBN

HC Wainwright & Co. analyst Patrick Trucchio has reiterated a 'Buy' rating on Cybin (AMEX:CYBN) and maintained a $10 price target.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:22 pm

IOVA

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) has announced the publication of abstracts for poster presentations reporting clinical data and trial design for tumor infiltrating lymphocyte (TIL) therapies at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting. The data includes a four-year analysis of pooled Cohorts 2 and 4 of the C-144-01 trial, which reports the longest follow-up data on lifileucel treatment outcomes in patients with anti–PD-1–refractory advanced melanoma treated with TIL therapy.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:20 pm

KTRA

Kintara Therapeutics (NASDAQ:KTRA) announced that its GBM AGILE study showed that VAL-083 did not perform better than the current standards of care in glioblastoma. As a result, the company is suspending the development of VAL-083 and shifting its focus to its REM-001 program and other strategic opportunities. The company also plans to conduct a review of potential strategic opportunities to maximize shareholder value. Kintara expects to enroll the first subject in a 15-patient CMBC study around the end of 2023, which is expected to be covered by a $2 million grant from the NIH.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:18 pm

LMDX

PETS

PINS

RNAZ

SRPT

WOLF

Several stocks are experiencing significant pre-market movements. LumiraDx Limited (LMDX) surged 38.8% after a Nasdaq delisting determination. TransCode Therapeutics (RNAZ) gained 30.1% after withdrawing a public offering. Pinterest (PINS) rose 16.5% following better-than-expected Q3 results and guidance. Wolfspeed (WOLF) rose 14.9% after Q1 earnings. On the downside, Sarepta Therapeutics (SRPT) fell 45.4% after reporting topline results from a pivotal study. PetMed Express (PETS) dipped 26.8% after weaker-than-expected Q2 sales.

Portfolio Pulse from Lisa Levin

October 31, 2023 | 1:15 pm

CACC

BMO Capital analyst James Fotheringham maintains a 'Market Perform' rating on Credit Acceptance (NASDAQ:CACC) but has lowered the price target from $354 to $347.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:15 pm

VCNX

Vaccinex, Inc. (NASDAQ:VCNX) will present findings from two Phase 2 studies of its lead product, pepinemab, at the Society for Immunotherapy of Cancer's Annual Meeting. The studies show pepinemab's ability to induce the formation of lymphoid structures in tumors, improving outcomes to immune checkpoint inhibitors. In one study, pepinemab combined with Merck's KEYTRUDA doubled objective responses and progression free survival in patients with hard-to-treat tumors. Another study with Emory University showed pepinemab, combined with nivolumab and/or ipilimumab, prevented tumor recurrence for over 2 years in patients.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:13 pm

CHGG

Chegg Inc's Q3 financial results show a revenue of $157.9 million, beating estimates of $152.67 million, and an EPS of 18 cents, beating estimates of 17 cents. However, revenues were down 4% YoY, with subscription services revenues and subscribers also decreasing. The company has started rolling out its new AI-powered user experience. Q4 revenue is expected to be between $185 million and $187 million. Piper Sandler analyst Arvind Ramnani maintained a Neutral rating for Chegg and lowered the price target from $13 to $9.

Portfolio Pulse from Adam Eckert

October 31, 2023 | 1:13 pm

TSXV:BRVO

BMO Capital analyst Raj Ray has maintained an 'Outperform' rating on Bravo Mining, but has lowered the price target from C$5.5 to C$5.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:12 pm